| 货号 | 规格 | 价格 | 上海 | 北京 | 武汉 | 南京 | 购买数量 |
|---|---|---|---|---|---|---|---|
S80448-1mg |
99.30% | ￥144.00 | 1 | - | - | - |
|
S80448-2mg |
99.30% | ￥280.00 | 5 | - | - | - |
|
S80448-5mg |
99.30% | ￥640.00 | 2 | - | - | - |
|
S80448-10mg |
99.30% | ￥1120.00 | 4 | - | - | - |
|
S80448-25mg |
99.30% | ￥2240.00 | 6 | - | - | - |
|
S80448-100mg |
99.30% | ￥3240.00 | 1 | - | - | - |
|
| 产品描述： | BMS-1 (PD-1/PD-L1 inhibitor 1, PD1-PDL1-IN1)是一种PD-1/PD-L1相互作用的小分子化合物抑制剂，IC50为6 nM | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶点： | PD-1/PD-L1 interaction(Cell-free assay):0.006 μM;Apoptosis;PD-1/PD-L1 | ||||||||||||||||||||
| 体外研究： | PD-1/PD-L1 inhibitor 1 causes half-reduced cell viability at lower concentrations in triple-negative breast cancer (TNBC), activates ERK in MDA-MB-231 and MCF7, significantly increases IL-8 expression in MDA-MB-231 and HCC1806 when administrated in combination with ERK1/2 inhibitor, also potently downregulates the IL-8 expression to its half amount in MDA-MB-231 | ||||||||||||||||||||
| 体内研究： | PD-1/PD-L1 inhibitor 1 combined with Jiedu Sangen Decoction (JSD) remarkably inhibits and reverses epithelial-mesenchymal transition (EMT) via PI3K/AKT signaling pathway | ||||||||||||||||||||
| 细胞实验： | Cell lines: MDA-MB-231 cells, HCC1937 cells, HCC1806 cells, MCF7 cells Concentrations: -- Incubation Time: 72 h Method: Cell proliferation is determined by the MTS assay. A total of 1-2×103 cells are plated in 100 μl medium in each well of a 96-well plate. After 24 h, PD-1/PD-L1 inhibitor 1 and ERK1/2 inhibitor are diluted to the desired concentrations in test medium (DMEM containing 1% fetal bovine serum) and added as single or as combined treatment in triplicate for 72 h. | ||||||||||||||||||||
| 动物实验： | Animal Models: Male specific pathogen free BALB/c mice of hepatic metastatic colorectal cancer (CRC) model Dosages: 100 µg Administration: i.p. | ||||||||||||||||||||
| 参考文献： | 1. WO/2015/034820, COMPOUNDS USEFUL AS IMMUNOMODULATORS. 2. Bräutigam K, et al. Inhibitors of PD-1/PD-L1 and ERK1/2 impede the proliferation of receptor positive and triple-negative breast cancer cell lines. J Cancer Res Clin Oncol. 2021;147(10):2923-2933. 3. Shan, Feiyu et al. Inhibition to Epithelial-Mesenchymal Transition and Metastatic Potential In Colorectal Cancer Cell By Combination of Traditional Chinese Medicine Formulation Jiedu Sangen Decoction and PD-L1 Inhibitor. Integrative cancer therapies vol. 19 (2020): 1534735420972486. | ||||||||||||||||||||
| 溶解性： | Soluble in DMSO、Ethanol、H2O | ||||||||||||||||||||
| 保存条件： | -20℃ | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京